Table 4. Normalized Dose Intensity 4-150... | American Society of Hematology

Table 4.

Normalized Dose Intensity^4-150 (Number of Patients)

	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Cycle 5	Cycle 6	Cycle 7	Cycle 8
Cyclophosphamide	100.0 (74)	100.0 (71)	100.0 (72)	100.0 (68)	100.0 (60)	100.0 (56)	97.2 (23)	96.3 (19)
Doxorubicin	100.0 (74)	100.0 (71)	100.0 (72)	100.0 (69)	100.0 (62)	100.0 (57)	98.5 (23)	96.3 (19)
VP-16	100.0 (73)	100.0 (71)	99.9 (71)	99.9 (68)	99.9 (52)	99.9 (59)	98.5 (23)	96.3 (19)
Ara-C	100.0 (71)	98.5 (61)	97.8 (68)	99.7 (58)	99.4 (56)	96.6 (54)	82.1 (20)	50.3 (14)
Bleomycin	100.0 (74)	100.0 (70)	100.0 (70)	100.0 (63)	100.0 (61)	100.0 (56)	100.0 (23)	100.0 (18)
Vincristine^4-151	100.0 (74)	100.0 (70)	100.0 (65)	100.0 (59)	100.0 (59)	100.0 (53)	100.0 (23)	100.0 (18)
Methotrexate	99.6 (72)	98.5 (69)	99.2 (69)	99.2 (64)	99.1 (62)	99.2 (58)	99.5 (24)	96.8 (19)
Cycle duration (days)^‡	22	22	23	22	27	22	22	21

	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Cycle 5	Cycle 6	Cycle 7	Cycle 8
Cyclophosphamide	100.0 (74)	100.0 (71)	100.0 (72)	100.0 (68)	100.0 (60)	100.0 (56)	97.2 (23)	96.3 (19)
Doxorubicin	100.0 (74)	100.0 (71)	100.0 (72)	100.0 (69)	100.0 (62)	100.0 (57)	98.5 (23)	96.3 (19)
VP-16	100.0 (73)	100.0 (71)	99.9 (71)	99.9 (68)	99.9 (52)	99.9 (59)	98.5 (23)	96.3 (19)
Ara-C	100.0 (71)	98.5 (61)	97.8 (68)	99.7 (58)	99.4 (56)	96.6 (54)	82.1 (20)	50.3 (14)
Bleomycin	100.0 (74)	100.0 (70)	100.0 (70)	100.0 (63)	100.0 (61)	100.0 (56)	100.0 (23)	100.0 (18)
Vincristine^4-151	100.0 (74)	100.0 (70)	100.0 (65)	100.0 (59)	100.0 (59)	100.0 (53)	100.0 (23)	100.0 (18)
Methotrexate	99.6 (72)	98.5 (69)	99.2 (69)	99.2 (64)	99.1 (62)	99.2 (58)	99.5 (24)	96.8 (19)
Cycle duration (days)^‡	22	22	23	22	27	22	22	21

Dose Intensity is expressed as a percentage of the designed dose. The figures above represent median % dose.

VCR had a dose cap of 2 mg. Therefore, the normalized dose intensity for those patients receiving 2 mg (with a BSA >1.43) was set to 100%.

Median cycle duration.